September 18, 2014 6:14 AM ET

Pharmaceuticals

Company Overview of Eurand N.V.

Company Overview

As of February 11, 2011, Eurand N.V. was acquired by Aptalis Pharma Inc. Eurand N.V. develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. Its technologies are used for applications in drug products in a range of therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition, and respiratory. The company’s products include EUR-1008, or ZENPEP for the treatment of exocrine pancreatic insufficiency; EUR-1002 or Amrix, an adjunct to rest and physical therapy for relief of muscle spasm associated with acute painful musculoskeletal conditions; EUR-1048 or Lamictal ODT, an orally disintegrating tablet formulation of lamotrigine for the treatment ...

Olympic Plaza

Fred Roeskestraat 123

Amsterdam,  1076 EE

Netherlands

Founded in 1984

583 Employees

Phone:

31 20 673 2744

Key Executives for Eurand N.V.

Eurand N.V. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
A.U.V. Holding B.V. Europe
Regilabs B.V. Europe
Centrafarm Nederland B.V. Europe
HAL Allergy Holding B.V. Europe
Abbott Biologicals B.V Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Eurand N.V., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.